|
Court Rejects Teva’s Arguments, Invalidates Its Crestor Patent
A federal appeals court has affirmed a lower court decision invalidating Teva’s stabilizing formulation patent for blockbuster AstraZeneca cholesterol drug Crestor.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapCourt Stays Seven Wyeth, Teva Pay-for-Delay Cases Pending Supreme Court Petitions PhRMA Asks Supreme Court to Reverse Third Circuit’s ‘Rogue’ Anti-Pay-for-Delay DecisionDistrict Court Stays Four Cephalon Pay-for-Delay Cases Pending Merck’s Supreme Court Petition
|
Subscribe
Archives